#CantorFitzgerald’s 2023 Virtual #BrainWeek Day One fireside chats, hosted by Senior Biotech Analyst, Charles C. Duncan, featured:

Xenon Pharmaceuticals Inc.: Ian Mortimer, President/CEO, and Chris Von Seggern, Chief Commercial Officer
• The Xenon management team discussed what differentiates #XEN1101 as a potential treatment for focal onset seizure, primary generalized tonic clonic seizures, and major depressive disorder

Prothena Corporation plc: Gene Kinney, President/ CEO, and Tran Nguyen, CFO/Chief Strategy Officer
• The Prothena team discussed its differentiated approach to developing monoclonal antibodies for proteinopathies and the development path for #PRX012
• In comparison to other anti-Aβ mAbs in development, ‘012 was specifically designed as a once-monthly subcutaneous injection, setting up an attractive target product profile

COMPASS Pathways: Kabir Nath, CEO, Michael Falvey, CFO, Dr. Guy Goodwin, CMO, and Dr. Steven Levine, SVP Medical Affairs
• Discussions with COMPASS management focused on the clinical potential and commercial prospects of intermittent #pharmacotherapy, #COMP360 (psilocybin), currently in the rigorously designed P3 program in treatment-resistant depression